prikaz prve stranice dokumenta Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?
Access restricted to students and staff of home institution
Scientific paper - Original scientific paper
Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?
Medical Hypotheses, 161 (2022); 110801. https://doi.org/10.1016/j.mehy.2022.110801
Golčić, Marin; Simetić, Luka; Majnarić, Tea; Golčić, Goran; Herceg, Davorin

Institutional repository: Repository of the University of Rijeka, Faculty of Medicine

Cite this document

Golčić, M., Simetić, L., Majnarić, T., Golčić, G. & Herceg, D. (2022). Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?. Medical Hypotheses, 161.. doi: 10.1016/j.mehy.2022.110801

Golčić, Marin, et al. "Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?." Medical Hypotheses, vol. 161, 2022. https://doi.org/10.1016/j.mehy.2022.110801

Golčić, Marin, Luka Simetić, Tea Majnarić, Goran Golčić and Davorin Herceg. "Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?." Medical Hypotheses 161 (2022). https://doi.org/10.1016/j.mehy.2022.110801

Golčić, M., et al. (2022) 'Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?', Medical Hypotheses, 161. doi: 10.1016/j.mehy.2022.110801

Golčić M, Simetić L, Majnarić T, Golčić G, Herceg D. Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?. Medical Hypotheses [Internet]. 2022 April [cited 2024 April 29];161. doi: 10.1016/j.mehy.2022.110801

M. Golčić, L. Simetić, T. Majnarić, G. Golčić and D. Herceg, "Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?", Medical Hypotheses, vol. 161, April 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:184:670239. [Accessed: 29 April 2024]

Metadata
Title (english)Could fecal microbial transplantation offer a new potential in the treatment of metastatic pancreatic ductal adenocarcinoma?
AuthorMarin Golčić https://orcid.org/0000-0002-3388-4813
AuthorLuka Simetić
AuthorTea Majnarić
AuthorGoran Golčić
AuthorDavorin Herceg
Author's institution(Clinical Hospital Center Rijeka)
Author's institutionUniversity of Rijeka
Faculty of Medicine
(Department of Oncology and Radiotherapy)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Radiotherapy and Oncology
Abstract (english)
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest cancers due to its aggressiveness and resistance to anti-cancer medications. Recent data suggest that solid tumors such as PDAC are infected with microbial agents, which can induce aggressive phenotype and metabolize chemotherapeutical agents. However, it was shown that gut microbiota can migrate to the pancreas and that fecal microbial transplantation (FMT) from longterm PDAC survivors can alter both gut and tumor microbiome, the immune response, and the growth of PDAC in a murine model. Although the effect of FMT on enhancing the immune response was exhibited in melanoma patients, there is no robust data to support the use of immunotherapy in the majority of PDAC patients, as chemotherapy remains the mainstay of treatment. Along with its direct cytotoxic effect, chemotherapy can also reduce ineffective cytokine sinks via lymphodepletion and increase translocation of the gut microbiota leading to stimulation of the immune response. However, chemotherapy requires a functional microbiota to exert those effects. We hypothesize that altering the microbiome with the FMT from the long-term PDAC survivors, combined with systemic treatment, can potentially enhance the relationship between chemotherapy, the immune system, and the microbiome. Albeit there is a lack of knowledge regarding the exact composition of the ideal donor microbiome and the optimal patient selection, due to the dismal prognosis of PDAC patients, such a trial could offer a low-risk, high-reward situation.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review - international
Publication versionPublished version
Journal titleMedical Hypotheses
Numberingvol. 161, 110801
p-ISSN0306-9877
DOIhttps://doi.org/10.1016/j.mehy.2022.110801
URN:NBNurn:nbn:hr:184:670239
Publication2022-04
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S030698772200041X
Type of resourceText
Access conditionsInstitutional access
Terms of useLicence In copyright icon
Created on2023-01-24 07:43:34